Tumor cells frequently undergo metabolic reprogramming, but it is unknown how these metabolic changes relate to drug resistance. A recent article now demonstrates that PI3K/AKT signaling causes a metabolic switch from glutaminolysis to aerobic glycolysis in Notch-dependent T cell acute lymphoblastic leukemia (T-ALL)
International audienceChanges in cell metabolism and metabolic adaptation are hallmark features of m...
Breast cancer is one of the leading causes of death in women in the United States. In general, patie...
Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the ...
Cancer outcome has improved since introduction of target therapy. However, treatment success is stil...
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 tha...
Leukemia cells as many tumor cells are characterized by metabolic peculiarities. Historically, leuke...
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 tha...
<p>It has been long known that many types of cancers have high metabolic requirements and use reprog...
The cellular receptor Notch1 is a central regulator of T-cell development, and as a consequence, Not...
The cellular receptor Notch1 is a central regulator of T-cell development, and as a consequence, Not...
Cancer cells, including leukemic cells, can react to therapeutic treatment by altering their metabol...
Cancer metabolism differs from that of the healthy cells in several aspects. Aerobic glycolysis (e.g...
Acute leukemias, classified as acute myeloid leukemia and acute lymphoblastic leukemia, represent th...
FLT3 internal tandem duplication (FLT3ITD) mutations are common in acute myeloid leukemia (AML) asso...
Acute leukemias, classified as acute myeloid leukemia and acute lymphoblastic leukemia, represent th...
International audienceChanges in cell metabolism and metabolic adaptation are hallmark features of m...
Breast cancer is one of the leading causes of death in women in the United States. In general, patie...
Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the ...
Cancer outcome has improved since introduction of target therapy. However, treatment success is stil...
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 tha...
Leukemia cells as many tumor cells are characterized by metabolic peculiarities. Historically, leuke...
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 tha...
<p>It has been long known that many types of cancers have high metabolic requirements and use reprog...
The cellular receptor Notch1 is a central regulator of T-cell development, and as a consequence, Not...
The cellular receptor Notch1 is a central regulator of T-cell development, and as a consequence, Not...
Cancer cells, including leukemic cells, can react to therapeutic treatment by altering their metabol...
Cancer metabolism differs from that of the healthy cells in several aspects. Aerobic glycolysis (e.g...
Acute leukemias, classified as acute myeloid leukemia and acute lymphoblastic leukemia, represent th...
FLT3 internal tandem duplication (FLT3ITD) mutations are common in acute myeloid leukemia (AML) asso...
Acute leukemias, classified as acute myeloid leukemia and acute lymphoblastic leukemia, represent th...
International audienceChanges in cell metabolism and metabolic adaptation are hallmark features of m...
Breast cancer is one of the leading causes of death in women in the United States. In general, patie...
Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in the ...
DOI
Add to ORKG